School of Pharmacy and Pharmaceutical Sciences
University of Colorado Denver|Anschutz Medical Campus, Aurora, Colorado, USA
Dr. Charmion Cruickshank-Quinn is from the Eastern Caribbean island of Dominica. She is an enthusiastic scientist who has made major contributions to the areas of chronic obstructive pulmonary (COPD) and autism using metabolomics. Her current interests are in lung disease research, omics integration, and biomarker discovery.
She received her BS in Chemistry from the State University of New York (SUNY) at Albany and her PhD in Chemistry from SUNY Buffalo. As part of her doctoral project, she performed method development to quantify glutathione in urine of autistic individuals and profiled samples to determine markers of oxidative stress and autism.
Dr. Cruickshank-Quinn moved to Colorado to pursue a Postdoctoral fellowship at National Jewish Health working in the laboratory of Dr. Nichole Reisdorph. There, she performed both targeted and untargeted liquid chromatography mass spectrometry (LC/MS)-based metabolomics. She currently works in the School of Pharmacy at the University of Colorado where she continues her postdoctoral fellowship in COPD research with Dr. Reisdorph. In the last 4 years, she has identified potential novel markers of COPD and has discovered and identified perturbed metabolic pathways in COPD patients. She is also working towards understanding the biological effects of cigarette smoking on a healthy metabolome using an emphysema mouse model, and determining parallels between mouse and human data for translation studies. Her other contribution to metabolomics involves taking a systems biology approach by integrating the genomics and metabolomics data sets. This provides a comprehensive understanding of the mechanisms of action for COPD, to pave the way for potential treatment or novel drug discovery or for prevention.